Impact of secukinumab on patient-reported outcomes in moderate to severe plaque psoriasis: a review of clinical studies. (1st February 2021)
- Record Type:
- Journal Article
- Title:
- Impact of secukinumab on patient-reported outcomes in moderate to severe plaque psoriasis: a review of clinical studies. (1st February 2021)
- Main Title:
- Impact of secukinumab on patient-reported outcomes in moderate to severe plaque psoriasis: a review of clinical studies
- Authors:
- Galluzzo, Marco
Talamonti, Marina
Manfreda, Valeria
Silvaggio, Dionisio
Tartaglia, Chiara
Roberto, Denis
Campione, Elena
Bianchi, Luca - Abstract:
- ABSTRACT: Introduction : Perception of illness varies among individuals and psoriasis of the same severity can be perceived in different ways by patients, making it essential to evaluate quality of life (QoL) since it can provide information on the impact of the disease on the patient's overall well-being. The use of patient-reported outcomes in clinical trials provides the ability to integrate objective clinical assessment with the patient's perception of their own state of health. Areas covered : The introduction of anti-IL17 agents in clinical practice has given patients the possibility to achieve a PASI90 response (almost clear skin) or even higher (complete clear skin) in the majority of patients. There is accumulating evidence in support of PASI90 response as the new standard goal for therapy based on its greater correlation with health-related QoL. The present review summarizes current knowledge of the effects of secukinumab on the QoL of patients with psoriasis using patient-reported outcome measures. Expert Opinion : Secukinumab, the first approved drug of this new class, has fully reached a new therapeutic paradigm not only in terms of clinical efficacy, but also in terms of patient satisfaction and self-rated health.
- Is Part Of:
- Expert opinion on biological therapy. Volume 21:Number 2(2021)
- Journal:
- Expert opinion on biological therapy
- Issue:
- Volume 21:Number 2(2021)
- Issue Display:
- Volume 21, Issue 2 (2021)
- Year:
- 2021
- Volume:
- 21
- Issue:
- 2
- Issue Sort Value:
- 2021-0021-0002-0000
- Page Start:
- 191
- Page End:
- 200
- Publication Date:
- 2021-02-01
- Subjects:
- Illness perception -- quality of life -- patient-reported outcomes -- secukinumab -- self-rated health
Gene therapy -- Periodicals
Protein drugs -- Periodicals
Peptide drugs -- Periodicals
Immunotherapy -- Periodicals
Drug delivery systems -- Periodicals
615.5 - Journal URLs:
- http://informahealthcare.com/journal/ebt ↗
http://www.ashley-pub.com/loi/ebt ↗
http://www.tandfonline.com/toc/iebt20/current ↗
http://informahealthcare.com ↗
http://miranda.ashley-pub.com/vl=2623054/cl=18/nw=1/rpsv/journal/journal1_home.htm ↗ - DOI:
- 10.1080/14712598.2021.1849131 ↗
- Languages:
- English
- ISSNs:
- 1471-2598
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3842.002940
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 24947.xml